subslover
3 weeks ago
Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study
NEW YORK, Oct. 29, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company dedicated to developing new generation therapies for unmet medical needs, is excited to announce highly promising early data from a preclinical study of its latest cancer treatment. The preliminary results demonstrate that the treatment successfully stabilizes tumor growth with remarkable consistency across subjects, showing potential as an effective therapeutic option in oncology. This study was performed and took place under a sponsored scientific research agreement with NC State University.
The study measured tumor volumes in treated and untreated subjects over the course of the experiment. Tumor volume measurements in the treated group exhibited minimal changes, suggesting that the treatment effectively inhibited tumor growth. Additionally, all tumors in the treated animals displayed remarkable consistency in volume, with standard deviation error bars barely visible—a strong indication of the treatment's uniformity and reproducibility in suppressing tumor growth.
"These early findings are incredibly encouraging and demonstrate that our treatment has the potential to halt tumor progression consistently across subjects," said Robb Knie, CEO of Hoth Therapeutics. "The stability and low variability observed in tumor volumes among treated animals are indicative of a promising therapeutic effect, and we're excited to move forward with further testing as we process additional tissue data."
Key observations from the initial data include:
Stabilized Tumor Growth: Tumor volumes in treated subjects remained remarkably stable over the course of the study, suggesting that the treatment may significantly inhibit tumor growth.
Consistency Across Subjects: Tumor sizes were highly consistent across all treated animals, as demonstrated by the minimal error bars on the graph. This uniform response highlights the treatment's potential reproducibility and reliability.
Comparison with Untreated Controls: In contrast, untreated subjects showed greater variability and an increase in tumor volume, underscoring the potential efficacy of the treatment in slowing or halting tumor growth.
As Hoth Therapeutics advances this research, the company will continue analyzing additional tissue data to further validate these results. The company is committed to moving forward with the development of this promising treatment and exploring its full potential for patients in need of effective cancer therapies.
For more information on Hoth Therapeutics' development programs, please visit www.hoththerapeutics.com.
subslover
1 month ago
Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway
NEW YORK, Oct. 15, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative treatments, is proud to announce the granting of a U.S. patent for its pioneering Alzheimer's treatment, HT-ALZ. This milestone patent secures the company's intellectual property rights to its novel therapeutic approach, as Hoth accelerates preparations for clinical trials.
HT-ALZ represents a breakthrough in Alzheimer's treatment, specifically targeting the Substance P/Neurokinin-1 Receptor pathway. This pathway is known to play a critical role in neuroinflammation, which is increasingly recognized as a driving factor in the progression of Alzheimer's disease. Preclinical studies have shown promising results, including reduced neuroinflammation and significant improvements in cognitive functions such as memory and learning.
The patent solidifies Hoth's leadership in the development of Alzheimer's therapies and paves the way for the next phase of human clinical trials. Formulation of HT-ALZ for these trials is currently underway, with the goal of advancing this promising treatment to patients as swiftly as possible.
Next Steps
As Hoth Therapeutics completes the formulation phase, the company will look to prepare clinical trials to further validate HT-ALZ's efficacy in humans. The upcoming trials will focus on demonstrating the drug's safety, tolerability, and effectiveness in slowing or reversing the cognitive decline associated with Alzheimer's disease.
Robb Knie, CEO of Hoth Therapeutics, commented, "This patent marks a significant achievement for Hoth as we progress HT-ALZ from the lab to clinical development. The preclinical data on neuroinflammation reduction and cognitive improvement offer great hope, and we are excited to take the next critical steps toward delivering a potentially life-changing therapy to Alzheimer's patients."
About HT-ALZ
HT-ALZ represents a novel approach in Alzheimer's research, focusing on the modulation of neuroinflammation, unlike many treatments that focus solely on amyloid plaques. Preclinical data has shown that HT-ALZ effectively reduces reactive astrocytes in the brain, cells that contribute to the inflammatory processes seen in Alzheimer's, leading to improved cognitive outcomes in experimental models.
For more information about Hoth Therapeutics and HT-ALZ, please visit www.hoththerapeutics.com.
TIMGZ
2 months ago
Hoth Therapeutics Received Institutional Review Board Approval From The Montefiore Medical Center And The Dana-Farber Cancer Institute To Proceed With Its First-In-Human Phase 2a Clinical Trial Of HT-001 For The Treatment Of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors
BENZINGA 10:37 AM ET 9/5/2024
Symbol Last Price Change
HOTH 1.24down +0.5301 (+74.6725%)
QUOTES AS OF 11:30:15 AM ET 09/05/2024
Dana-Farber Cancer Institute in Boston, MA and Montefiore Medical Center in New York, NY Join Clinical Trial
NEW YORK, Sept. 5, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc.(HOTH) , a patient-focused biopharmaceutical company, today announced today that it has received Institutional Review Board approval from the Montefiore Medical Center and the Dana-Farber Cancer Institute to proceed with its First-in-Human (FIH) Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi).
subslover
2 months ago
Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001
Cancer Patient Ceased Treatment After One Week Due to Rapid Success
In the reported case, the patient, a 59-year-old female undergoing treatment at George Washington University for metastatic breast cancer, experienced significant improvement in symptoms just one week after initiating HT-001 therapy. Due to the swift resolution of lesions and the alleviation of discomfort, the patient was able to discontinue the treatment after just seven days. Over the following three weeks, no new lesions developed, further highlighting the potential of HT-001 as an effective and safe therapy for EGFRI-associated PPEs.
NEW YORK, Sept. 5, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing next-generation therapies for unmet medical needs, is excited to announce positive data from the treatment of epidermal growth factor receptor inhibitor (EGFRI) associated papulopustular eruptions (PPEs) with its novel therapeutic HT-001. During this first-of-its-kind human patient case, the patient was able to cease treatment after just one week due to the rapid and successful resolution of symptoms, marking a significant advancement in managing a common and debilitating side effect experienced by cancer patients undergoing EGFRI therapy.
EGFRIs are widely used to treat various cancers of epithelial origin but are frequently associated with cutaneous side effects, most notably PPEs like acneiform rash, which can occur in up to 90% of patients. These PPEs can cause significant discomfort, including pruritus and burning, and often lead to interruptions or discontinuation of critical cancer therapies. HT-001 offers a new approach to managing these skin toxicities, showing rapid symptom relief without compromising the patient's ongoing cancer treatment.
In the reported case, the patient, a 59-year-old female undergoing treatment at George Washington University for metastatic breast cancer, experienced significant improvement in symptoms just one week after initiating HT-001 therapy. Due to the swift resolution of lesions and the alleviation of discomfort, the patient was able to discontinue the treatment after just seven days. Over the following three weeks, no new lesions developed, further highlighting the potential of HT-001 as an effective and safe therapy for EGFRI-associated PPEs.
"We are thrilled with the positive data from this first investigator led study patient case," said Robb Knie, CEO of Hoth Therapeutics. "HT-001 has the potential to significantly improve the quality of life for cancer patients suffering from EGFRI-induced skin toxicities. This rapid and successful treatment is an important milestone as we continue to explore HT-001's potential to meet this critical unmet need."
A Phase 2a clinical trial is currently underway to further evaluate the efficacy and safety of HT-001 in the management of EGFRI-associated skin toxicities. Current sites include MD Anderson Cancer Center, University of Miami, Dana Farber Cancer Institute, University of California Irvine, the George Washington University, Montefiore Medical Center, and Northwell Health, Inc. For more information, please visit clinical trials.
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ .
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronaviru
subslover
4 months ago
Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment
Treatment of pre-clinical subjects showed cognitive benefits that suggest HT-ALZ's mode of action may involve a reduction in brain inflammation, thereby improving cognitive outcomes for Alzheimer's patients.
HT-ALZ's pre-clinical significance lies in its ability to demonstrate marked cognitive improvement and quality of life for subjects suffering from Alzheimer's disease
The pre-clinical research shows compelling evidence of HT-ALZ's capacity to improve memory tasks related to the hippocampus and sensorimotor gating, showcasing an important step forward in Alzheimer's disease treatment.
NEW YORK, July 24, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has signed an agreement with LTS Therapy Systems, LLC ("LTS"), to develop and manufacture the HT-ALZ oral film prototype. HT-ALZ is being developed as a novel therapeutic solution for Alzheimer's Disease based on its exciting preclinical results released earlier this year. HT-ALZ's pre-clinical significance lies in its ability to restore cognitive functions and improve quality of life for subjects suffering from Alzheimer's disease.
"Hoth is excited to announce this partnership and the next milestone in our development of HT-ALZ," stated Robb Knie, Chief Executive Officer. "We are leveraging LTS's expertise to develop and manufacture the oral film prototypes needed for this particular population and leveraging our positive preclinical results to advance our Alzheimer's therapeutic ."
The HT-ALZ prototype development and manufacturing work by LTS will be used to support a future Investigational New Drug (IND) Application to initiate clinical trials. For more information on Hoth Therapeutics and our innovative approach to Alzheimer's disease treatment with HT-ALZ, please visit https://hoththerapeutics.com.
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ .
News
Market Data
Register for streaming realtime charts, analysis tools, and prices.
glenn1919
2 months ago
georgie18
2 months ago
Surfacetite
2 months ago
motleytool
2 months ago
PonkenPlonken
2 months ago
peterus
2 months ago
TrendTrade2016
2 months ago
TheFinalCD
2 months ago
Nebuchadnezzar
3 months ago
Monksdream
4 months ago
